DOI QR코드

DOI QR Code

Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer

  • Cao, Wa (Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine) ;
  • Li, Ai-Wu (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine) ;
  • Ren, Sheng-Xiang (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine) ;
  • Chen, Xiao-Xia (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine) ;
  • Li, Wei (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine) ;
  • Gao, Guang-Hui (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine) ;
  • He, Ya-Yi (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine) ;
  • Zhou, Cai-Cun (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine)
  • Published : 2014.08.30

Abstract

Background: Chemotherapy is the mainstay of treatment for the majority of patients with advanced non-small cell lung cancer (NSCLC) without driver mutations and many receive therapies beyond first-line. Second-line chemotherapy has been disappointing both in terms of response rate and survival and we know relatively little about the prognostic factors. Materials and Methods: One thousand and eight patients with advanced NSCLC who received second-line chemotherapy after progression were reviewed in Shanghai Pulmonary Hospital, China, from September 2005 to July 2010. We analyzed the effects of potential prognostic factors on the outcomes of second-line chemotherapy (overall response rate, ORR; progression free survival, PFS; overall survival, OS). Results: The response and progression free survival of first-line chemotherapy affects the ORR, PFS and OS of second-line chemotherapy (ORR: CR/PR 15.4%, SD 10.1%, PD2.3%, p<0.001; PFS: CR/PR 3.80 months, SD 2.77 months, PD 2.03 months, p<0.001; OS: CR/PR 11.60 months, SD 10.33 months, PD 6.57 months, p=0.578, p<0.001, p<0.001, respectively). On multivariate analysis, better response to first-line therapy (CR/PR: HR=0.751, p=0.002; SD: HR=0.781, p=0.021) and progression within 3-6 months (HR=0.626, p<0.001), together with adenocarcinoma (HR=0.815, p=0.017), without liver metastasis (HR=0.541, p=0.001), never-smoker (HR=0.772, p=0.001), and ECOG PS 0-1 (HR=0.745, p=0.021) were predictors for good OS following second-line chemotherapy. Conclusions: Patients who responded to first-line chemotherapy had a better outcome after second-line therapy for advanced NSCLC, and the efficacy of first-line chemotherapy, period of progression, histology, liver metastasis, smoking status and ECOG PS were independent prognostic factors for OS.

Keywords

NSCLC;second-line chemotherapy;first-line chemotherapy;prognostic factor

References

  1. Ali I, M Ali K, Mehmet K, et al (2012). Prognostic factors for second-line treatment of advanced Non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev, 13, 1281-4. https://doi.org/10.7314/APJCP.2012.13.4.1281
  2. Ardizzoni A, Tiseo M, Boni L, et al (2012). Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol, 30, 4501-7. https://doi.org/10.1200/JCO.2012.43.6758
  3. Caponi S, Vasile E, Ginocchi L, et al (2010). Second-line treatment for non-small-cell lung cancer: one size does not fit all. Clinical Lung Cancer, 11, 320-7. https://doi.org/10.3816/CLC.2010.n.040
  4. de Marinis F, Ricciardi S (2011). Second-line treatment options in advanced non-small cell lung cancer. Eur J Cancer, 47, 258-71.
  5. Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C (2012). Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer, 77, 116-20. https://doi.org/10.1016/j.lungcan.2012.01.013
  6. Favaretto A, Pasello G, Magro C, Schettino C, Gridelli C (2009). Second and third line treatment in non-small cell lung cancer. Crit Rev Oncol Hematol, 71, 117-26. https://doi.org/10.1016/j.critrevonc.2009.01.009
  7. Gridelli C, de Marinis F, Cappuzzo F, et al (2014). Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer, 15, 173-81. https://doi.org/10.1016/j.cllc.2013.12.002
  8. Gao G, Ren S, Li A, et al (2012). Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer, 131, 822-9. https://doi.org/10.1002/ijc.27396
  9. Greillier L, Barlesi F (2012). Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?. Rev Mal Respir, 29, 4-6 (in French). https://doi.org/10.1016/j.rmr.2011.12.006
  10. Gomez P, Yorke R, Ayala AG, Ro JY (2012). Solid-pseudopapillary neoplasm of pancreas with long delayed liver metastasis. Ann Diagn Pathol, 16, 380-4. https://doi.org/10.1016/j.anndiagpath.2011.02.008
  11. Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
  12. Ishizuka M, Kita J, Shimoda M et al (2012). Impact of grading of liver metastasis on postoperative outcome in patients with liver metastases from colorectal cancer. Hepatogastroenterology, 59, 54-8.
  13. Lal R, Enting D, Kristeleit H. Systemic treatment of non-smallcell lung cancer (2011). Eur J Cancer, 47, 375-7. https://doi.org/10.1016/j.ejca.2010.09.043
  14. Moro-Sibilot D, Nishino M, Jackman DM, Hatabu H, et al (2010). New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR, 195, 221-8. https://doi.org/10.2214/AJR.09.3928
  15. Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6. https://doi.org/10.7314/APJCP.2013.14.8.4661
  16. Pao W, Chmielecki J. Rational (2010). Biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 10, 760-74. https://doi.org/10.1038/nrc2947
  17. Qi WX, Shen Z, Lin F et al (2012). Comparison of the efficacy and safety of EGFR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small cell lung cancer: a systematic revies and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-82. https://doi.org/10.7314/APJCP.2012.13.10.5177
  18. Ramalingam SS, Owonikoko TK, Khuri FR (2011). Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin, 61, 91-112. https://doi.org/10.3322/caac.20102
  19. Ren S, Kuang P, Zheng L, et al (2012). Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys, 64, 155-60. https://doi.org/10.1007/s12013-012-9384-8
  20. Ren S, Chen X, Kuang P, et al (2012). Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer, 118, 5588-94. https://doi.org/10.1002/cncr.27603
  21. Sun JM, Oh DY, Lee SH, et al (2010). The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer, 68, 427-32. https://doi.org/10.1016/j.lungcan.2009.07.013
  22. Tadashi Maeda, Hiroshi U, Masahiro T, et al (2000). Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol, 30, 534-41. https://doi.org/10.1093/jjco/hyd139
  23. Vergnenegre A, Corre R, Berard H, et al (2011). Costeffectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thoracic Oncol, 6, 161-8. https://doi.org/10.1097/JTO.0b013e318200f4c1
  24. Vergnenegre A, Smit EF, et al (2010). Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Curr Med Res Opin, 26, 2661-72. https://doi.org/10.1185/03007995.2010.525489
  25. Wu M, Zhao J, Song SW, et al (2010). EGFR mutations are associated with prognosis but not with the response to front line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer, 67, 343-7. https://doi.org/10.1016/j.lungcan.2009.04.011
  26. Weiss GJ, Rosell R, Fossella F, et al (2007). The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol, 18, 453-60.
  27. Zhou C, Wu Y-L, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42. https://doi.org/10.1016/S1470-2045(11)70184-X
  28. Zietemann V, Duell T (2011). Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer, 73, 70-7. https://doi.org/10.1016/j.lungcan.2010.10.017
  29. Zabaleta J, Aguinagalde B, Fuentes MG, et al (2011). Survival after lung metastasectomy for colorectal cancer: Importance of previous liver metastasis as a prognostic factor. Eur J Surg Oncol, 37, 786-90. https://doi.org/10.1016/j.ejso.2011.05.014

Cited by

  1. Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147
  2. Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2987
  3. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? pp.1744-8301, 2019, https://doi.org/10.2217/fon-2018-0948